Published in Medical Letter on the CDC and FDA, March 6th, 2005
Clearance was granted in a recent meeting between senior company officials and representatives of the U.S. Food & Drug Administration (FDA) at which the FDA representatives stated it appears reasonable for Syneron to submit a 510(k) pre-market notification to the FDA for marketing clearance of its VelaSmooth system in the U.S.
The VelaSmooth is sold in Europe and Canada and in other countries around the world. It was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.